{"id":55970,"date":"2023-04-18T21:04:37","date_gmt":"2023-04-18T19:04:37","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/exai-bio-presents-new-non-small-cell-lung-cancer-early-detection-data-at-the-american-association-for-cancer-research-aacr-2023-annual-meeting\/"},"modified":"2023-04-18T21:04:37","modified_gmt":"2023-04-18T19:04:37","slug":"exai-bio-presents-new-non-small-cell-lung-cancer-early-detection-data-at-the-american-association-for-cancer-research-aacr-2023-annual-meeting","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/exai-bio-presents-new-non-small-cell-lung-cancer-early-detection-data-at-the-american-association-for-cancer-research-aacr-2023-annual-meeting\/","title":{"rendered":"Exai Bio Presents New Non-Small Cell Lung Cancer Early Detection Data at the American Association for Cancer Research (AACR) 2023 Annual Meeting"},"content":{"rendered":"
\n

\nFindings demonstrate highly sensitive and specific detection of the earliest and smallest tumors using Exai\u2019s novel RNA- and AI-based liquid biopsy platform<\/i><\/p>\n

PALO ALTO, Calif.–(BUSINESS WIRE)–Exai Bio today announced new data demonstrating that its novel RNA- and AI-based platform detected non-small cell lung cancer with high accuracy, at the earliest stages and for the smallest tumors, in both training and validation cohorts. In the independent validation cohort, stage I sensitivity was 96% and tumor size T1a-b sensitivity was 94%, at 90% specificity. These findings continue to highlight the power of Exai’s proprietary technology to detect cancer at its earliest stages from a blood draw. This study will be presented today at the American Association for Cancer Research (AACR) 2023 annual meeting.<\/p>\n

<\/a><\/p>\n

\n“These results demonstrate the unique advantages of our RNA-based liquid biopsy platform in early detection,” said Patrick Arensdorf, Chief Executive Officer of Exai. “We set the bar high in this study, emphasizing small and early stage tumors, in order to address head-on the unmet need for earlier lung cancer detection. Exai\u2019s platform reveals actionable insights into novel cancer biology in order to achieve our ultimate goal of improving patient outcomes.\u201d<\/p>\n

\nToday\u2019s non-small cell lung cancer results at AACR expand a growing body of evidence that Exai\u2019s platform can be used across multiple tumor types and clinical applications, using standard blood samples. Previously, Exai has presented breast cancer early detection and screening data<\/a> at the San Antonio Breast Cancer Symposium (SABCS) 2022, monitoring and molecular residual disease detection data<\/a> in breast cancer at SABCS 2021, and colorectal cancer early detection and screening data<\/a> at the 2022 European Society for Medical Oncology (ESMO) meeting.<\/p>\n

\nExai\u2019s platform uses RNA sequencing to identify a novel category of cancer-associated, small non-coding RNAs, termed orphan non-coding RNAs (oncRNAs). OncRNAs are actively secreted from living cancer cells and are stable and abundant in the blood of cancer patients. Exai has created a catalog of hundreds of thousands of oncRNAs and thousands of patient oncRNA profiles, spanning all major cancer types. When combined with Exai\u2019s proprietary artificial intelligence, this unique platform has several scientific and practical advantages over tests that focus on circulating tumor DNA including sensitivity, specificity and informative properties for active cancer biology. Exai\u2019s universal platform can be used across multiple cancer care settings such as screening and early detection, monitoring, molecular residual disease and therapy selection.<\/p>\n

\nAACR Presentation Details<\/b><\/p>\n

\nPresentation Title: <\/b>Blood-based Early Detection of Non Small Cell Lung Cancer Using Orphan Noncoding RNAs<\/p>\n

\nSession Title:<\/b> Increasing the Clinical Utility of Cell Free DNA Testing<\/p>\n

\nDate:<\/b> Tuesday, 4\/18\/23, 2:30 – 4:30 PM EDT<\/p>\n

\nAuthors:<\/b> Mehran Karimzadeh, Jeffrey Wang, Aiden Sababi, Dare Afolabi, Ti Lam, Alice Huang, Diana Corti, Kristle Garcia, Seda Kilinc, Allen Zhao, Jeff J Wang, Taylor Cavazos, Patrick Arensdorf, Kimberly Chau, Helen Li, Hani Goodarzi, Lisa Fish, Fereydoun Hormozdiari, Babak Alipanahi<\/p>\n

\nAbout Exai Bio<\/b><\/p>\n

\nExai Bio is a next-generation liquid biopsy company. Its mission is to enable a world where cancer can be detected early, diagnosed accurately, treated in a personalized and targeted way, and ultimately cured. The company\u2019s proprietary RNA- and AI-based liquid biopsy technology delivers clinical insights into cancer biology to enable the earliest, most accurate diagnosis of cancer. For more information, please visit us on www.exai.bio<\/a> and follow us on Twitter<\/a> and LinkedIn<\/a>.<\/p>\n

Contacts<\/b> <\/p>\n

\nKim Maxwell Brown<\/a>
kimb@exai.bio<\/a>
(617) 960-6685<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Findings demonstrate highly sensitive and specific detection of the earliest and smallest tumors using Exai\u2019s novel RNA- and AI-based liquid biopsy platform PALO ALTO, Calif.–(BUSINESS WIRE)–Exai Bio today announced new data demonstrating that its novel RNA- and AI-based platform detected non-small cell lung cancer with high accuracy, at the earliest stages and for the smallest … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-55970","6":"format-standard","7":"category-industry"},"yoast_head":"\nExai Bio Presents New Non-Small Cell Lung Cancer Early Detection Data at the American Association for Cancer Research (AACR) 2023 Annual Meeting - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/exai-bio-presents-new-non-small-cell-lung-cancer-early-detection-data-at-the-american-association-for-cancer-research-aacr-2023-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Exai Bio Presents New Non-Small Cell Lung Cancer Early Detection Data at the American Association for Cancer Research (AACR) 2023 Annual Meeting - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Findings demonstrate highly sensitive and specific detection of the earliest and smallest tumors using Exai\u2019s novel RNA- and AI-based liquid biopsy platform PALO ALTO, Calif.–(BUSINESS WIRE)–Exai Bio today announced new data demonstrating that its novel RNA- and AI-based platform detected non-small cell lung cancer with high accuracy, at the earliest stages and for the smallest ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/exai-bio-presents-new-non-small-cell-lung-cancer-early-detection-data-at-the-american-association-for-cancer-research-aacr-2023-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-18T19:04:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230418005412\/en\/1766140\/21\/Exai_biz_wire_logo_feb_2023.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exai-bio-presents-new-non-small-cell-lung-cancer-early-detection-data-at-the-american-association-for-cancer-research-aacr-2023-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exai-bio-presents-new-non-small-cell-lung-cancer-early-detection-data-at-the-american-association-for-cancer-research-aacr-2023-annual-meeting\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Exai Bio Presents New Non-Small Cell Lung Cancer Early Detection Data at the American Association for Cancer Research (AACR) 2023 Annual Meeting\",\"datePublished\":\"2023-04-18T19:04:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exai-bio-presents-new-non-small-cell-lung-cancer-early-detection-data-at-the-american-association-for-cancer-research-aacr-2023-annual-meeting\\\/\"},\"wordCount\":578,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exai-bio-presents-new-non-small-cell-lung-cancer-early-detection-data-at-the-american-association-for-cancer-research-aacr-2023-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230418005412\\\/en\\\/1766140\\\/21\\\/Exai_biz_wire_logo_feb_2023.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exai-bio-presents-new-non-small-cell-lung-cancer-early-detection-data-at-the-american-association-for-cancer-research-aacr-2023-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exai-bio-presents-new-non-small-cell-lung-cancer-early-detection-data-at-the-american-association-for-cancer-research-aacr-2023-annual-meeting\\\/\",\"name\":\"Exai Bio Presents New Non-Small Cell Lung Cancer Early Detection Data at the American Association for Cancer Research (AACR) 2023 Annual Meeting - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exai-bio-presents-new-non-small-cell-lung-cancer-early-detection-data-at-the-american-association-for-cancer-research-aacr-2023-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exai-bio-presents-new-non-small-cell-lung-cancer-early-detection-data-at-the-american-association-for-cancer-research-aacr-2023-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230418005412\\\/en\\\/1766140\\\/21\\\/Exai_biz_wire_logo_feb_2023.jpg\",\"datePublished\":\"2023-04-18T19:04:37+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exai-bio-presents-new-non-small-cell-lung-cancer-early-detection-data-at-the-american-association-for-cancer-research-aacr-2023-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exai-bio-presents-new-non-small-cell-lung-cancer-early-detection-data-at-the-american-association-for-cancer-research-aacr-2023-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exai-bio-presents-new-non-small-cell-lung-cancer-early-detection-data-at-the-american-association-for-cancer-research-aacr-2023-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230418005412\\\/en\\\/1766140\\\/21\\\/Exai_biz_wire_logo_feb_2023.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230418005412\\\/en\\\/1766140\\\/21\\\/Exai_biz_wire_logo_feb_2023.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exai-bio-presents-new-non-small-cell-lung-cancer-early-detection-data-at-the-american-association-for-cancer-research-aacr-2023-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Exai Bio Presents New Non-Small Cell Lung Cancer Early Detection Data at the American Association for Cancer Research (AACR) 2023 Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Exai Bio Presents New Non-Small Cell Lung Cancer Early Detection Data at the American Association for Cancer Research (AACR) 2023 Annual Meeting - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/exai-bio-presents-new-non-small-cell-lung-cancer-early-detection-data-at-the-american-association-for-cancer-research-aacr-2023-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Exai Bio Presents New Non-Small Cell Lung Cancer Early Detection Data at the American Association for Cancer Research (AACR) 2023 Annual Meeting - Pharma Trend","og_description":"Findings demonstrate highly sensitive and specific detection of the earliest and smallest tumors using Exai\u2019s novel RNA- and AI-based liquid biopsy platform PALO ALTO, Calif.–(BUSINESS WIRE)–Exai Bio today announced new data demonstrating that its novel RNA- and AI-based platform detected non-small cell lung cancer with high accuracy, at the earliest stages and for the smallest ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/exai-bio-presents-new-non-small-cell-lung-cancer-early-detection-data-at-the-american-association-for-cancer-research-aacr-2023-annual-meeting\/","og_site_name":"Pharma Trend","article_published_time":"2023-04-18T19:04:37+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230418005412\/en\/1766140\/21\/Exai_biz_wire_logo_feb_2023.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/exai-bio-presents-new-non-small-cell-lung-cancer-early-detection-data-at-the-american-association-for-cancer-research-aacr-2023-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/exai-bio-presents-new-non-small-cell-lung-cancer-early-detection-data-at-the-american-association-for-cancer-research-aacr-2023-annual-meeting\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Exai Bio Presents New Non-Small Cell Lung Cancer Early Detection Data at the American Association for Cancer Research (AACR) 2023 Annual Meeting","datePublished":"2023-04-18T19:04:37+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/exai-bio-presents-new-non-small-cell-lung-cancer-early-detection-data-at-the-american-association-for-cancer-research-aacr-2023-annual-meeting\/"},"wordCount":578,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/exai-bio-presents-new-non-small-cell-lung-cancer-early-detection-data-at-the-american-association-for-cancer-research-aacr-2023-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230418005412\/en\/1766140\/21\/Exai_biz_wire_logo_feb_2023.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/exai-bio-presents-new-non-small-cell-lung-cancer-early-detection-data-at-the-american-association-for-cancer-research-aacr-2023-annual-meeting\/","url":"https:\/\/pharma-trend.com\/en\/exai-bio-presents-new-non-small-cell-lung-cancer-early-detection-data-at-the-american-association-for-cancer-research-aacr-2023-annual-meeting\/","name":"Exai Bio Presents New Non-Small Cell Lung Cancer Early Detection Data at the American Association for Cancer Research (AACR) 2023 Annual Meeting - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/exai-bio-presents-new-non-small-cell-lung-cancer-early-detection-data-at-the-american-association-for-cancer-research-aacr-2023-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/exai-bio-presents-new-non-small-cell-lung-cancer-early-detection-data-at-the-american-association-for-cancer-research-aacr-2023-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230418005412\/en\/1766140\/21\/Exai_biz_wire_logo_feb_2023.jpg","datePublished":"2023-04-18T19:04:37+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/exai-bio-presents-new-non-small-cell-lung-cancer-early-detection-data-at-the-american-association-for-cancer-research-aacr-2023-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/exai-bio-presents-new-non-small-cell-lung-cancer-early-detection-data-at-the-american-association-for-cancer-research-aacr-2023-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/exai-bio-presents-new-non-small-cell-lung-cancer-early-detection-data-at-the-american-association-for-cancer-research-aacr-2023-annual-meeting\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230418005412\/en\/1766140\/21\/Exai_biz_wire_logo_feb_2023.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230418005412\/en\/1766140\/21\/Exai_biz_wire_logo_feb_2023.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/exai-bio-presents-new-non-small-cell-lung-cancer-early-detection-data-at-the-american-association-for-cancer-research-aacr-2023-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Exai Bio Presents New Non-Small Cell Lung Cancer Early Detection Data at the American Association for Cancer Research (AACR) 2023 Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55970","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=55970"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55970\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=55970"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=55970"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=55970"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}